| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 11.56% | Piper Sandler | $45 → $40 | Maintains | Neutral |
| 11/02/2023 | 36.66% | Needham | $52 → $49 | Maintains | Buy |
| 09/22/2023 | 11.56% | Stifel | $45 → $40 | Maintains | Hold |
| 09/15/2023 | 25.51% | Piper Sandler | $50 → $45 | Maintains | Neutral |
| 09/15/2023 | 81.29% | Mizuho | → $65 | Reiterates | Buy → Buy |
| 09/15/2023 | — | Benchmark | Downgrades | Buy → Hold | |
| 09/15/2023 | 45.03% | Needham | $54 → $52 | Maintains | Buy |
| 09/13/2023 | 81.29% | Mizuho | → $65 | Reiterates | Buy → Buy |
| 09/13/2023 | 25.51% | Stifel | → $45 | Reiterates | Hold → Hold |
| 08/21/2023 | 25.51% | Stifel | $50 → $45 | Maintains | Hold |
| 08/14/2023 | 58.97% | Stephens & Co. | → $57 | Reiterates | Overweight → Overweight |
| 08/04/2023 | 58.97% | Stephens & Co. | $71 → $57 | Maintains | Overweight |
| 08/03/2023 | 39.45% | Piper Sandler | $65 → $50 | Maintains | Neutral |
| 08/03/2023 | 61.76% | Needham | $75 → $58 | Maintains | Buy |
| 08/03/2023 | 33.87% | Canaccord Genuity | $77 → $48 | Downgrades | Buy → Hold |
| 06/12/2023 | 53.4% | Stifel | $60 → $55 | Maintains | Hold |
| 06/08/2023 | 114.75% | Canaccord Genuity | → $77 | Reiterates | → Buy |
| 06/07/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/24/2023 | 109.18% | Needham | → $75 | Reiterates | Buy → Buy |
| 05/04/2023 | 137.07% | Stephens & Co. | → $85 | Reiterates | → Overweight |
| 05/04/2023 | 134.28% | Needham | $78 → $84 | Maintains | Buy |
| 04/17/2023 | 81.29% | Piper Sandler | → $65 | Initiates Coverage On | → Neutral |
| 02/22/2023 | 137.07% | Stephens & Co. | → $85 | Reiterates | → Overweight |
| 02/22/2023 | 117.54% | Needham | $83 → $78 | Maintains | Buy |
| 02/06/2023 | — | BTIG | Downgrades | Buy → Neutral | |
| 02/01/2023 | 109.18% | Benchmark | $78 → $75 | Maintains | Buy |
| 01/30/2023 | 123.12% | Canaccord Genuity | $79 → $80 | Maintains | Buy |
| 01/20/2023 | 120.33% | Canaccord Genuity | $76 → $79 | Maintains | Buy |
| 12/28/2022 | 137.07% | Stephens & Co. | $91 → $85 | Maintains | Overweight |
| 12/08/2022 | 67.34% | Stifel | → $60 | Initiates Coverage On | → Hold |
| 11/07/2022 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 11/03/2022 | 123.12% | BTIG | $103 → $80 | Maintains | Buy |
| 11/03/2022 | 131.49% | Needham | $110 → $83 | Maintains | Buy |
| 10/14/2022 | 145.43% | Canaccord Genuity | $97 → $88 | Maintains | Buy |
| 10/14/2022 | 153.8% | Stephens & Co. | → $91 | Reinstates | → Overweight |
| 10/13/2022 | 137.07% | Mizuho | → $85 | Initiates Coverage On | → Buy |
| 08/11/2022 | 248.63% | Jefferies | $165 → $125 | Maintains | Buy |
| 08/11/2022 | 226.31% | Benchmark | $97 → $117 | Maintains | Buy |
| 08/11/2022 | 206.79% | Needham | $87 → $110 | Maintains | Buy |
| 04/26/2022 | 148.22% | Canaccord Genuity | $81 → $89 | Maintains | Buy |
| 04/08/2022 | 142.64% | Needham | → $87 | Initiates Coverage On | → Buy |
| 03/18/2022 | 173.32% | BTIG | → $98 | Upgrades | Neutral → Buy |
| 07/09/2021 | 318.35% | Oppenheimer | → $150 | Initiates Coverage On | → Perform |
| 05/06/2021 | 318.35% | Canaccord Genuity | $128 → $150 | Maintains | Buy |
| 01/19/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 08/31/2020 | 61.76% | Sidoti & Co. | → $58 | Upgrades | Neutral → Buy |
| 08/06/2020 | 84.07% | Benchmark | $50 → $66 | Maintains | Buy |
| 06/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/15/2020 | 53.4% | Jefferies | → $55 | Initiates Coverage On | → Buy |
| 04/14/2020 | 22.72% | Canaccord Genuity | $48 → $44 | Maintains | Buy |
| 03/23/2020 | 3.19% | Stephens & Co. | $56 → $37 | Maintains | Overweight |
| 12/04/2019 | 28.29% | BTIG | → $46 | Initiates Coverage On | → Buy |
| 11/19/2019 | 39.45% | Benchmark | $54 → $50 | Maintains | Buy |
| 11/11/2019 | 25.51% | Canaccord Genuity | $40 → $45 | Maintains | Buy |
What is the target price for Staar Surgical (STAA)?
The latest price target for Staar Surgical (NASDAQ: STAA) was reported by Piper Sandler on November 2, 2023. The analyst firm set a price target for $40.00 expecting STAA to rise to within 12 months (a possible 11.56% upside). 33 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Staar Surgical (STAA)?
The latest analyst rating for Staar Surgical (NASDAQ: STAA) was provided by Piper Sandler, and Staar Surgical maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Staar Surgical (STAA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Staar Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Staar Surgical was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Staar Surgical (STAA) correct?
While ratings are subjective and will change, the latest Staar Surgical (STAA) rating was a maintained with a price target of $45.00 to $40.00. The current price Staar Surgical (STAA) is trading at is $35.85, which is out of the analyst's predicted range.